Objectives: To describe the sources of uncertainty in prognosticating devastating brain injury, the role of the intensivist in prognostication, and ethical considerations in prognosticating devastating brain injury in the ICU. Data Sources: A PubMed literature review was performed. Study Selection: Articles relevant to prognosis in intracerebral hemorrhage, acute ischemic stroke, traumatic brain injury, subarachnoid hemorrhage, and postcardiac arrest anoxic encephalopathy were selected. Data Extraction: Data regarding definition and prognosis of devastating brain injury were extracted. Themes related to how clinicians perform prognostication and their accuracy were reviewed and extracted. Data Synthesis: Although there are differences in pathophysiology and therefore prognosis in the various etiologies of devastating brain injury, some common themes emerge. Physicians tend to have fairly good prognostic accuracy, especially in severe cases with poor prognosis. Full supportive care is recommended for at least 72 hours from initial presentation to maximize the potential for recovery and minimize secondary injury. However, physician approaches to the timing of and recommendations for withdrawal of life-sustaining therapy have a significant impact on mortality from devastating brain injury. Conclusions: Intensivists should consider the modern literature describing prognosis for devastating brain injury and provide appropriate time for patient recovery and for discussions with the patient’s surrogates. Surrogates wish to have a prognosis enumerated even when uncertainty exists. These discussions must be handled with care and include admission of uncertainty when it exists. Respect for patient autonomy remains paramount, although physicians are not required to provide inappropriate medical therapies. The authors have disclosed that they do not have any potential conflicts of interest. Address requests for reprints to: Alexandra K. Pratt, MD, Department of Critical Care, MedStar Washington Hospital Center, 110 Irving St NW, Suite 4B-42, Washington, DC 20010. E-mail: akapratt@gmail.com Copyright © by 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
from Emergency Medicine via xlomafota13 on Inoreader http://bit.ly/2FHT33b
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Ravulizumab (ravulizumab-cwvz; ULTOMIRIS™), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Ph...
-
http://bit.ly/2TO0eLw
-
Objectives: High-flow nasal cannula is increasingly used in the management of respiratory failure. However, little is known about its impact...
-
Abstract Objective Long-acting synthetic somatostatin analogues (SSA) are an essential part of the treatment of neuroendocrine neoplasms...
-
Abstract Chronic low-grade inflammation is now widely accepted as one of the most important contributors to metabolic disorders. Glycoprot...
-
Abstract Purpose To analyze the differences in outcomes between primary and secondary definitive osteosynthesis for fractures of the lower...
-
Abstract Introduction Mesenchymal stem cell (MSC) chondrogenesis is associated with increases in intracellular reactive oxygen species (...
-
Training in teamwork behaviour improves technical resuscitation performance. However, its effect on patient outcome is less clear, partly be...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου